Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours

References

• Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14:284–297. doi:10.1007/s13311-017-0519-x28281173
   PubMed Web of Science ®Google Scholar
• Cerna T, Stiborova M, Adam V, Kizek R, Eckschlager T. Nanocarrier drugs in the treatment of brain tumors. J Cancer Metastasis Treat. 2016;2(10):407. doi:10.20517/2394-4722.2015.95
   Google Scholar
• Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014;19:403–413. doi:10.1634/theoncologist.2013-034524664484
   PubMed Web of Science ®Google Scholar
• Jakola AS, Skjulsvik AJ, Myrmel KS, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–1948. doi:10.1093/annonc/mdx23028475680
   PubMed Web of Science ®Google Scholar
• Panciani PP, Fontanella M, Schatlo B, et al. Fluorescence and image guided resection in high grade glioma. Clin Neurol Neurosurg. 2012;114(1):37–41. doi:10.1016/j.clineuro.2011.09.00121963142
   PubMed Web of Science ®Google Scholar
• Darlix A, Mandonnet E, Freyschlag CF, et al. Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. Neurooncol Pract. 2019;6(4):264–273. doi:10.1093/nop/npy05131386080
   PubMed Web of Science ®Google Scholar
• Caffo M, Cardali S, Fazzari E, Barresi V, Caruso G. Nanoparticles drug-delivery systems and antiangiogenic approaches in the treatment of gliomas. Glioma. 2018;1(6):183. doi:10.4103/glioma.glioma_43_18
   Google Scholar
• Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Front Physiol. 2018;9:1–14. doi:10.3389/fphys.2018.0017029377031
   PubMed Web of Science ®Google Scholar
• Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther. 2010;128:1–36. doi:10.1016/j.pharmthera.2010.04.01520546782
   PubMed Web of Science ®Google Scholar
• Mathieu D, Fortin D. The role of chemotherapy in the treatment of malignant astrocytomas. Can J Neurol Sci. 2006;33(2):127–140. doi:10.1017/S031716710000488116736721
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood–brain barrier. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. J Cereb Blood Flow Metab. 2012;32:1959–1972. doi:10.1007/bf0068622922929442
   PubMed Web of Science ®Google Scholar
• Greig NH, Genka S, Daly EM, Sweeney DJ, Rapoport SI. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol. 1990;25:311–319. doi:10.1007/BF006862292306790
   PubMed Web of Science ®Google Scholar
• Ke XY, Zhao BJ, Zhao X, et al. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials. 2010;31(22):5855–5864. doi:10.1016/j.biomaterials.2010.03.07920430438
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779. doi:10.1212/01.wnl.0000304121.57857.3818316689
   PubMed Web of Science ®Google Scholar
• Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. 2004;3(5):430–446. doi:10.1038/nrd138015136790
   PubMed Web of Science ®Google Scholar
• Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs. 2009;18(10):1549–1557. doi:10.1517/13543780903183528
   PubMed Web of Science ®Google Scholar
• Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15(11):1311–1333. doi:10.1101/gad.89160111390353
   PubMed Web of Science ®Google Scholar
• Fukai J, Nishio K, Itakura T, Koizumi F. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci. 2008;99(10):2062–2069. doi:10.1111/j.1349-7006.2008.00945.x19016767
   PubMed Web of Science ®Google Scholar
• Crombet T, Torres O, Rodríguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma. 2001;20(2):131–136. doi:10.1089/0272457015205763411394532
   PubMedGoogle Scholar
• Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol. 2005;207(2):224–231. doi:10.1002/path.182316021678
   PubMed Web of Science ®Google Scholar
• Holmen SL, Williams BO. Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 2005;65(18):8250–8255. doi:10.1158/0008-5472.CAN-05-117316166301
   PubMed Web of Science ®Google Scholar
• Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010;96(3):393–402. doi:10.1007/s11060-009-9976-319688297
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Kalofonos HP. Molecularly targeted therapies for malignant gliomas. Mol Med. 2009;15(3–4):115–122. doi:10.2119/molmed.2008.0012319148300
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther. 2003;3(5):595–614. doi:10.1586/14737140.3.5.59514599084
   PubMedGoogle Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462–7469. doi:10.1158/0008-5472.CAN-05-007116103100
   PubMed Web of Science ®Google Scholar
• Da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist. 2002;7(1):17–33. doi:10.1634/theoncologist.7-1-1711854544
   PubMed Web of Science ®Google Scholar
• Bredel M, Pollack IF. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta Neurochir (Wien). 1997;139(11):1000–1013. doi:10.1007/bf014115529442212
   PubMed Web of Science ®Google Scholar
• Sharif TR, Sharif M. Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol. 1999;15(2):237–243.10402232
   PubMed Web of Science ®Google Scholar
• Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia. 2005;7(4):356–368. doi:10.1593/neo.0459515967113
   PubMed Web of Science ®Google Scholar
• Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29(12):5171–5184.20044633
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7(4):209–219. doi:10.1038/nrclinonc.2010.2120234352
   PubMed Web of Science ®Google Scholar
• Yuan R, Kay A, Berg W, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2(1):45. doi:10.1186/1756-8722-2-4519860903
   PubMedGoogle Scholar
• Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23(23):5294–5304. doi:10.1200/JCO.2005.23.62215998902
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8. doi:10.1371/journal.pmed.005000818215105
   PubMed Web of Science ®Google Scholar
• Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 1999;80:764–772. doi:10.1002/(sici)1097-0215(19990301)80:5<764::aid-ijc22>3.0.co;2-j10048980
   PubMed Web of Science ®Google Scholar
• Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs. 2000;9:2167–2177. doi:10.1517/13543784.9.9.2167
   PubMed Web of Science ®Google Scholar
• Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2):380–389. doi:10.1097/00006123-200108000-0002211504114
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2:45–59. doi:10.1093/neuonc/2.1.4511302254
   PubMed Web of Science ®Google Scholar
• Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100:323–331. doi:10.1007/s00401000018010965803
   PubMed Web of Science ®Google Scholar
• Li M, Deng H, Peng H, Wang Q. Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol. 2014;14(1):415–432. doi:10.1166/jnn.2014.875724730272
   PubMed Web of Science ®Google Scholar
• Argaw AT, Zhang Y, Snyder BJ, et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol. 2006;177:5574–5584. doi:10.4049/jimmunol.177.8.557417015745
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106:829–838. doi:10.1172/JCI936911018070
   PubMed Web of Science ®Google Scholar
• Schlageter KE, Molnar P, Lapin GD, et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res. 1999;58:312–328. doi:10.1006/mvre.1999.218810527772
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv. 2012;6:671–676. doi:10.1517/17425247.2012.682726
   Google Scholar
• Gaoe H, Pang Z, Pan S, et al. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res. 2012;35(2):333–341. doi:10.1007/s12272-012-0214-822370788
   PubMed Web of Science ®Google Scholar
• Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37. doi:10.1016/j.jconrel.2016.02.02626892752
   PubMed Web of Science ®Google Scholar
• Schiffer D, Annovazzi L, Caldera V, Mellai M. On the origin and growth of gliomas. Anticancer Res. 2010;30:1977–1998.20651342
   PubMed Web of Science ®Google Scholar
• Allhenn D, Boushehri MAS, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436:299–310. doi:10.1016/j.ijpharm22721856
   PubMed Web of Science ®Google Scholar
• Zhang TT, Li W, Meng G, Wang P, Liao W. Strategies for transporting nanoparticles across the blood‑brain barrier. Biomater Sci. 2016;4:219–229. doi:10.1039/c5bm00383k26646694
   PubMed Web of Science ®Google Scholar
• Battaglia L, Muntoni E, Chirio D, et al. Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment. Nanomedicine. 2017;12(6):639–656. doi:10.2217/nnm-2016-038028186465
   PubMed Web of Science ®Google Scholar
• Muntoni E, Martina K, Marini E, et al. Methotrexate-loaded solid lipid nanoparticles: protein functionalization to improve brain biodistribution. Pharmaceutics. 2019;11:2. doi:10.3390/pharmaceutics11020065
   Web of Science ®Google Scholar
• Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol. 2014;247:291–307. doi:10.1007/s00232-014-9637-024573305
   PubMed Web of Science ®Google Scholar
• Miao D, Jiang M, Liu Z, et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol Pharm. 2014;11:90–101. doi:10.1021/mp400189j24295590
   PubMed Web of Science ®Google Scholar
• Kuo YC, Shih-Huang CY. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J Drug Target. 2013;21:730–738. doi:10.3109/1061186X.2013.81209423815407
   PubMed Web of Science ®Google Scholar
• Shilo M, Motiei M, Hana P, Popovtzer R. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale. 2014;6:2146–2152. doi:10.1039/c3nr04878k24362586
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I. Blood–brain barrier function of P-glycoprotein. Adv Drug Deliv Rev. 1997;25:287–298. doi:10.1016/S0169-409X(97)00504-8
   Web of Science ®Google Scholar
• Schinkel AH. P-glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev. 1999;36:179–194. doi:10.1016/s0169-409x(98)00085-410837715
   PubMed Web of Science ®Google Scholar
• Kuntner C, Bankstahl JP, Bankstahl M, et al. Dose–response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood–brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging. 2010;37:942–953. doi:10.1007/s00259-009-1332-520016890
   PubMed Web of Science ®Google Scholar
• Mastronardi L, Puzzilli F, Ruggeri A. Tamoxifen as a potential treatment of glioma. Anticancer Drugs. 1998;9:581–586. doi:10.1097/00001813-199808000-000019773800
   PubMed Web of Science ®Google Scholar
• Miller DS, Bauer B, Hartz AMS. Modulation of P-glycoprotein at the blood–brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196–209. doi:10.1124/pr.107.0710918560012
   PubMed Web of Science ®Google Scholar
• Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine. 2013;9:111–121. doi:10.1016/j.nano.2012.03.00322426195
   PubMed Web of Science ®Google Scholar
• Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004;64:920–927. doi:10.1158/0008-5472.can-03-207314871821
   PubMed Web of Science ®Google Scholar
• Michael JS, Lee B, Zhang M, Yu JS. Nanotechnology for treatment of glioblastoma multiforme. J Transl Intern Med. 2018;6(3):128–133. doi:10.2478/jtim-2018-0025
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. doi:10.1038/nature0312815549107
   PubMed Web of Science ®Google Scholar
• Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133:983–995. doi:10.1093/brain/awq04220375133
   PubMed Web of Science ®Google Scholar
• Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8:3274–3284. doi:10.4161/cc.8.20.970119770585
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845. doi:10.1038/359843a01279431
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993;268:21513–21518.8408001
   PubMed Web of Science ®Google Scholar
• Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3ʹ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991;88:5680–5684. doi:10.1073/pnas.88.13.56802062846
   PubMed Web of Science ®Google Scholar
• Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275:25130–25138. doi:10.1074/jbc.M00191420010833514
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–1259. doi:10.1158/1078-0432.CCR-06-230917317837
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729. doi:10.1200/JCO.2007.12.244017947719
   PubMed Web of Science ®Google Scholar
• Chen WL, Wang CC, Lin YJ, Wu CP, Hsieh CH. Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. J Transl Med. 2015;13:389. doi:10.1186/s12967-015-0758-826711814
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M, Peira E, et al. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology. 2015;26(25):255102. doi:10.1088/0957-4484/26/25/25510226043866
   PubMed Web of Science ®Google Scholar
• Sack‑Zschauer M, Bader S, Brenneisen P. Cerium oxide nanoparticles as novel tool in glioma treatment: an in vitro study. J Nanomed Nanotechnol. 2017;8:474. doi:10.4172/2157-7439.1000474
   Google Scholar
• Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361:2235–2242. doi:10.1016/S0140-6736(03)13780-412842380
   PubMed Web of Science ®Google Scholar
• Guiot C, Zullino S, Priano L, Cavalli R. The physics of drug delivery across the blood brain barrier. Ther Deliv. 2016;7(3):153–155. doi:10.4155/tde-2016-000126893246
   PubMedGoogle Scholar
• Lollo G, Vincent M, Ullio-Gamboa G, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm. 2015;495(2):972–980. doi:10.1016/j.ijpharm.2015.09.06226428632
   PubMed Web of Science ®Google Scholar
• Lopez-Bertoni H, Kozielski KL, Rui Y, et al. Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival. Nano Lett. 2018;18(7):4086–4094. doi:10.1021/acs.nanolett.8b0039029927251
   PubMed Web of Science ®Google Scholar
• Bastiancich C, Vanvarenberg K, Ucakar B, et al. Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J Control Release. 2016;225:283–293. doi:10.1016/j.jconrel.2016.01.05426829100
   PubMed Web of Science ®Google Scholar
• Bastiancich C, Lemaire L, Bianco J, et al. Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models. Nanomedicine. 2018;13:1999–2013. doi:10.2217/nnm-2018-005730204064
   PubMed Web of Science ®Google Scholar
• Bastiancich C, Bozzato E, Luyten U, et al. Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment. Int J Pharm. 2019;559:220–227. doi:10.1016/j.ijpharm.2019.01.04230703501
   PubMedGoogle Scholar
• Landhuis E. Ultrasound for the brain. Nature. 2017;551:257–259. doi:10.1038/d41586-017-05479-7
   PubMed Web of Science ®Google Scholar
• Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016;8:343re22016. doi:10.1126/scitranslmed.aaf6086
   Web of Science ®Google Scholar
• Zhang H, Wang T, Qiu W, et al. Monitoring the opening and recovery of the blood − brain barrier with noninvasive molecular imaging by biodegradable ultrasmall Cu2−xSe nanoparticles. Nano Lett. 2018;18(8):4985–4992. doi:10.1021/acs.nanolett.8b0181829995426
   PubMed Web of Science ®Google Scholar
• Liu Z, Ren F, Zhang H, et al. Biomaterials boosting often overlooked long wavelength emissions of rare-earth nanoparticles for NIR-II fluorescence imaging of orthotopic glioblastoma. Biomaterials. 2019;219:119364. doi:10.1016/j.biomaterials.2019.11936431352311
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang T, Liu H, et al. Second near-infrared photodynamic therapy and chemotherapy of orthotopic malignant glioblastoma with ultra-small Cu2−xSe nanoparticles. Nanoscale. 2019:7600–7608. doi:10.1039/c9nr01789e.30968107
   PubMed Web of Science ®Google Scholar
• Frosina G. Nanoparticle-mediated drug delivery to high-grade gliomas. Nanomed Nanotechnol Biol Med. 2016;12(4):1083–1093. doi:10.1016/j.nano.2015.12.375
   PubMed Web of Science ®Google Scholar
• Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87(3):433–444. doi:10.1016/j.ejpb.2014.05.00424833004
   PubMed Web of Science ®Google Scholar
• Grant GA, Abbott NJ, Janigro D. Understanding the physiology of the blood-brain barrier: in vitro models. News Physiol Sci. 1998;13:287–293. doi:10.1152/physiologyonline.1998.13.6.28711390805
   PubMedGoogle Scholar
• Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol. 2017;133(2):263–282. doi:10.1007/s00401-017-1671-428074274
   PubMed Web of Science ®Google Scholar
• Becher B, Prat A, Antel JP. Brain–immune connection: immunoregulatory properties of CNS-resident cells. Glia. 2000;29:293–304.10652440
   PubMed Web of Science ®Google Scholar
• Hickey WF. Basic principles of immunologic surveillance of the normal central nervous system. Glia. 2001;36:118–124. doi:10.1002/glia.110111596120
   PubMed Web of Science ®Google Scholar
• Biasibetti E, Valazza A, Capucchio MT, et al. Comparison of allogeneic and syngeneic rat glioma models by using MRI and histopathologic evaluation. Comp Med. 2017;67(2):147–156.28381315
   PubMed Web of Science ®Google Scholar
• Bianco J, Bastiancich C, Joudiou N, et al. Novel model of orthotopic U-87 MG glioblastoma resection in athymic nude mice. J Neurosci Methods. 2017;284:96–102. doi:10.1016/j.jneumeth.2017.04.01928472680
   PubMed Web of Science ®Google Scholar
• Chen Z, Lai X, Song S, Zhu X, Zhu J. Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv. 2015;23:1369–1373. doi:10.3109/10717544.2015.103885726017099
   PubMed Web of Science ®Google Scholar
• Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016;23:2720–2725. doi:10.3109/10717544.2015.105843426203691
   PubMed Web of Science ®Google Scholar
• Jin J, Bae KH, Yang H, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011;22:2568–2572. doi:10.1021/bc200406n22070554
   PubMed Web of Science ®Google Scholar
• Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–332. doi:10.1016/j.jconrel.2017.08.03328844756
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Controlled Release. 2004;99:259–269. doi:10.1016/j.jconrel.2004.07.006
   PubMed Web of Science ®Google Scholar
• Estella-hermoso De Mendoza A, Préat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011;156(3):421–426. doi:10.1016/j.jconrel.2011.07.03021821074
   PubMed Web of Science ®Google Scholar
• Lockman PR, Koziara J, Roder KE, et al. In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticles. Pharm Res. 2003;20:705–713. doi:10.1023/a:102349201585112751624
   PubMed Web of Science ®Google Scholar
• Zara GP, Bargoni A, Cavalli R, et al. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci. 2002;91(5):1324–1333. doi:10.1002/jps.1012911977108
   PubMed Web of Science ®Google Scholar
• Liu L, Ni F, Zhang J, et al. Silver nanocrystals sensitize magnetic‑nanoparticle‑mediated thermo‑induced killing of cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011;43:316–323. doi:10.1093/abbs/gmr01521377996
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007;124:163. doi:10.1016/j.jconrel.2007.09.00717964677
   PubMed Web of Science ®Google Scholar
• Huang S, Li J, Han L, et al. Dual targeting effect of Angiopep-2-modified, DNA loaded nanoparticles for glioma. Biomaterials. 2011;32:6832. doi:10.1016/j.biomaterials.2011.05.06421700333
   PubMed Web of Science ®Google Scholar
• Dal Magro R, Albertini B, Beretta S, et al. Artificial apolipoprotein corona enables nanoparticle brain targeting. Nanomed. 2017;14(2):429–438. doi:10.1016/j.nano.2017.11.008
   PubMed Web of Science ®Google Scholar
• Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm. 2013;85:488–502. doi:10.1016/j.ejpb.2013.08.01123994244
   PubMed Web of Science ®Google Scholar
• Chen H, Qin Y, Zhang Q, et al. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci. 2011;44:164. doi:10.1016/j.ejps.2011.07.00721782939
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CCM, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014;9(1):e82331. doi:10.1371/journal.pone.008233124416140
   PubMed Web of Science ®Google Scholar
• Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R, Diwan PV. β-hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. Nanomedicine. 2013;9:388–397. doi:10.1016/j.nano.2012.08.00422960191
   PubMed Web of Science ®Google Scholar
• De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol. 2007;47:323–355. doi:10.1146/annurev.pharmtox.47.120505.10523716961459
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Jeppesen M, Pilgaard L, et al. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J Drug Deliv. 2013;2013:209205. doi:10.1155/2013/20920524175095
   PubMedGoogle Scholar
• Chen C, Duan Z, Yuan Y, et al. Peptide‑22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. ACS Appl Mater Interfaces. 2017;9:5864–5873. doi:10.1021/acsami.6b1583128128553
   PubMed Web of Science ®Google Scholar
• Hu Q, Gu G, Liu Z, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials. 2013;34:1135. doi:10.1016/j.biomaterials.2012.10.04823146434
   PubMed Web of Science ®Google Scholar
• Gu G, Xia H, Hu Q, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34:196. doi:10.1016/j.biomaterials.2012.09.04423069707
   PubMed Web of Science ®Google Scholar
• Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicin-loaded liposomes. J Control Release. 2011;152:402. doi:10.1016/j.jconrel.2011.03.01421435361
   PubMed Web of Science ®Google Scholar
• Long W, Yi Y, Chen S, et al. Potential new therapies for pediatric diffuse intrinsic pontine glioma. Front Pharmacol. 2017;8:1–13. doi:10.3389/fphar.2017.0049528149278
   PubMed Web of Science ®Google Scholar
• Altaner C, Altanerova C. Stem cell based glioblastoma cell therapy. Neoplasma. 2012;59(6):756–760. doi:10.4149/neo_2012_9522862177
   PubMed Web of Science ®Google Scholar
• Kwon S, Yoo KH, Sym SJ, Khang D. Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration. Int J Nanomedicine. 2019;14:5925–5942. doi:10.2147/IJN.S21792331534331
   PubMed Web of Science ®Google Scholar
• Wang X, Gao J, Ouyang X, et al. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomedicine. 2018;13:5231–5248. doi:10.2147/IJN.S16714230237710
   PubMed Web of Science ®Google Scholar
• Suryaprakash S, Lao YH, Cho HY, et al. Engineered mesenchymal stem cell/nanomedicine spheroid as an active drug delivery platform for combinational glioblastoma therapy. Nano Lett. 2019;19(3):1701–1705. doi:10.1021/acs.nanolett.8b0469730773888
   PubMed Web of Science ®Google Scholar
• Huang W-C, Lin L, Chiang W-H, et al. Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma. J Control Release. 2017;254:119–130. doi:10.1016/j.jconrel.2017.03.03528336375
   PubMed Web of Science ®Google Scholar
• McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol. 2019;20(3):24. doi:10.1007/s11864-019-0619-430790064
   PubMed Web of Science ®Google Scholar
• Eagles ME, Nassiri F, Badhiwala JH, et al. Dendritic cell vaccines for high-grade gliomas. Ther Clin Risk Manag. 2018;14:1299–1313. doi:10.2147/TCRM.S13586530100728
   PubMed Web of Science ®Google Scholar
• Huang J, Liu F, Liu Z, et al. Immune checkpoint in glioblastoma: promising and challenging. Front Pharmacol. 2017;8:242. doi:10.3389/fphar.2017.0024228536525
   PubMed Web of Science ®Google Scholar
• Xue J, Zhao Z, Zhang L, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12:692–700. doi:10.1038/nnano.2017.5428650441
   PubMed Web of Science ®Google Scholar
• Wu M, Zhang H, Tie C, et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat Commun. 2018;9:4777. doi:10.1038/s41467-018-07250-630429468
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Desai AS, Linette GP, et al. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429–1438. doi:10.1093/neuonc/noy03229509936
   PubMed Web of Science ®Google Scholar
• Migliorini D, Dietrich PY, Stupp R, et al. CAR T-cell therapies in glioblastoma: a first look. Clin Cancer Res. 2017;24(3):535–540. doi:10.1158/1078-0432.CCR-17-287129158268
   PubMed Web of Science ®Google Scholar
• Zhu H, You Y, Shen Z, et al. EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity. Pathol Oncol Res. 2020. doi:10.1007/s12253-019-00759-1
   Web of Science ®Google Scholar
• Harris JC, Scully MA, Day ES. Cancer cell membrane-coated nanoparticles for cancer management. Cancers. 2019;11:1836. doi:10.3390/cancers11121836
   PubMed Web of Science ®Google Scholar
• Jin J, Krishnamachary B, Barnett JD, et al. Human cancer cell membrane-coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces. 2019;11(8):7850–7861. doi:10.1021/acsami.8b2230930707559
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51. doi:10.1038/nbt.278624406927
   PubMed Web of Science ®Google Scholar
• Musazzi UM, Marini V, Casiraghi A, Minghetti P. Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials? Drug Discov Today. 2017;22(6):870–882. doi:10.1016/j.drudis.2017.01.01628189800
   PubMed Web of Science ®Google Scholar
• Hafner A, Lovric J, Lakos GP, Pepić I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005–1023. doi:10.2147/IJN.S5535924600222
   PubMed Web of Science ®Google Scholar
• EMA. Reflection Paper on Nanotechnology-Based Medicinal Products for Human Use; 2006.
   Google Scholar
• Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9(1):1–14. doi:10.1016/j.nano.2012.05.01322684017
   PubMed Web of Science ®Google Scholar
• Battaglia L, Ugazio E. Lipid nano- and microparticles: an overview of patent-related research. J Nanomater. 2019;2834941. doi:10.1155/2019/2834941
   Web of Science ®Google Scholar
• Linsinger TP, Chaudhry Q, Dehalu V, et al. Validation of methods for the detection and quantification of engineered nanoparticles in food. Food Chem. 2013;138(2–3):1959–1966. doi:10.1016/j.foodchem.2012.11.07423411331
   PubMed Web of Science ®Google Scholar
• Corner J, Owen A, Kwade A, Van de Voorde M. Scale‐up and cGMP manufacturing of nanodrug delivery systems for clinical investigations. Pharm Nanotechnol. 2016. doi:10.1002/9783527800681.ch12
   Google Scholar
• Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19:1567–1576. doi:10.1158/1078-043223349317
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Arbiser J, Zelnak A, et al. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11:203–222. doi:10.1038/nrclinonc.2014.2524569448
   PubMed Web of Science ®Google Scholar
• Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3–13. doi:10.1023/a:102624650078814649881
   PubMed Web of Science ®Google Scholar
• Whittle JR, Lickliter JD, Gan HK, et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015;22:1889‑1894. doi:10.1016/j.jocn.2015.06.005
   PubMed Web of Science ®Google Scholar
• Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer. 2001;92:1936–1942. doi:10.1002/1097-0142(20011001)92:7<1936::aid-cncr1712>3.0.co;2-h11745268
   PubMed Web of Science ®Google Scholar
• Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004;100:1199–1207. doi:10.1002/cncr.2007315022287
   PubMed Web of Science ®Google Scholar
• Glas M, Koch H, Hirschmann B, et al. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology. 2008;72(5–6):302–307. doi:10.1159/000113052
   Web of Science ®Google Scholar
• Huncharek M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev. 1998;24:307–316. doi:10.1016/s0305-7372(98)90054-89861194
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1118. doi:10.1016/s0140-6736(02)08091-111937180
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, Di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83–95. doi:10.1016/j.ccr.2006.11.02117222792
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27(15):2542–2552. doi:10.1200/JCO.2008.19.935619332720
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol. 2001;55(2):91–100. doi:10.1023/a:101332983206711817706
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2008;27(5):740–745. doi:10.1200/JCO.2008.16.305519114704
   PubMed Web of Science ®Google Scholar
• Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579–584. doi:10.1200/JCO.2008.18.963919075262
   PubMed Web of Science ®Google Scholar
• Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005;56(1):155–162. doi:10.1227/01.neu.0000145865.25689.5515617598
   PubMed Web of Science ®Google Scholar
• Belda-Iniesta C, JdC C, Saenz EC, Gutiérrez M, Perona R, Barón MG. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther. 2006;5(8):912–914. doi:10.4161/cbt.5.8.311816929166
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596–1603. doi:10.1093/annonc/mdp03219491283
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis. 2005;34(2):181–185. doi:10.1016/j.bcmd.2004.11.00615727903
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Kuhn J, Robins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005;23(27):6647–6656. doi:10.1200/JCO.2005.10.06816170172
   PubMed Web of Science ®Google Scholar
• Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol. 2005;23(16_suppl):1504. doi:10.1200/jco.2005.23.16suppl.1504
   Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009;15(10):3617–3623. doi:10.1093/neuonc/nop04219417015
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23(4):357–361. doi:10.1007/s10637-005-1444-016012795
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271–7278. doi:10.1158/1078-0432.CCR-06-124917189398
   PubMed Web of Science ®Google Scholar
• Levin VA, Phuphanich S, Yung WKA, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78(3):295–302. doi:10.1007/s11060-005-9098-516636750
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610–5617. doi:10.1200/JCO.2008.16.751018981465
   PubMed Web of Science ®Google Scholar
• Charest G, Sanche L, Fortin D, Mathieu D, Paquette B. Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:244–249. doi:10.1016/j.ijrobp.2011.10.05422284691
   PubMed Web of Science ®Google Scholar
• Qu J, Zhang L, Chen Z, et al. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Drug Deliv. 2016;23:3408–3416. doi:10.1080/10717544.2016.118946527181462
   PubMed Web of Science ®Google Scholar
• Shatsberg Z, Zhang X, Ofek P, et al. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy. J Control Release. 2016;239:159–168. doi:10.1016/j.jconrel.2016.08.02927569663
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded 14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14(2):97–105. doi:10.1080/1061186060063613516608736
   PubMed Web of Science ®Google Scholar
• Tian XH, Lin XN, Wei F, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine. 2011;6:445–452. doi:10.2147/ijn.s1657021445277
   PubMed Web of Science ®Google Scholar
• Wang CX, Huang LS, Hou LB, et al. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res. 2009;1261:91–99. doi:10.1016/j.brainres.2009.01.01119401168
   PubMed Web of Science ®Google Scholar
• Jain D, Bajaj A, Athawale R, et al. Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies. Drug Deliv. 2016;23(3):999–1016. doi:10.3109/10717544.2014.92657425026415
   PubMed Web of Science ®Google Scholar
• Xu HL, Mao KL, Huang YP, et al. Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects. Nanoscale. 2016;8(29):14222–14236. doi:10.1039/c6nr02448c27396404
   PubMed Web of Science ®Google Scholar
• Fundarò A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res. 2000;42(4):337–343.10987994
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target. 2002;10(4):327–335. doi:10.1080/1061186029003186812164381
   PubMed Web of Science ®Google Scholar
• Zong Z, Hua L, Wang Z, et al. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy. Drug Deliv. 2019;26(1):34–44. doi:10.1080/10717544.2018.153489730744436
   PubMed Web of Science ®Google Scholar
• Lu F, Pang Z, Zhao J, et al. Poly (ε-Caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 2017;12:2117–2127. doi:10.2147/IJN.S12342228356732
   PubMed Web of Science ®Google Scholar
• Wang X, Xiong Z, Liu Z, Huang X, Jiang X. Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma. Sci Rep. 2018;8(1):1–11. doi:10.1038/s41598-018-30072-x29311619
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA. 1996;93:14164–14169. doi:10.1073/pnas.93.24.141648943078
   PubMed Web of Science ®Google Scholar
• Huang JL, Jiang G, Song QX, et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun. 2017;8:1–18. doi:10.1038/ncomms1514428232747
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang J, Meng F, Zhong Z. Apolipoprotein e peptide-directed chimeric polymersomes mediate an ultrahigh-efficiency targeted protein therapy for glioblastoma. ACS Nano. 2018;12(11):11070–11079. doi:10.1021/acsnano.8b0526530395440
   PubMed Web of Science ®Google Scholar
• Rajora MA, Ding L, Valic M, et al. Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma. Chem Sci. 2017;8(8):5371–5384. doi:10.1039/c7sc00732a28970916
   PubMed Web of Science ®Google Scholar
• Liu X, Cui W, Li B, Hong Z. Targeted therapy for glioma using cyclic RGD-entrapped polyionic complex nanomicelles. Int J Nanomedicine. 2012;7:2853. doi:10.2147/IJN.S2978822745548
   PubMed Web of Science ®Google Scholar
• Miura Y, Takenaka T, Toh K, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano. 2013;7:8583–8592. doi:10.1021/nn402662d24028526
   PubMed Web of Science ®Google Scholar
• Mao J, Ran D, Xie C, Shen Q, Wang S, Lu W. EGFR/EGFRvIII dual-targeting peptide-mediated drug delivery for enhanced glioma therapy. ACS Appl Mater Interfaces. 2017;9(29):24462–24475. doi:10.1021/acsami.7b0561728685576
   PubMed Web of Science ®Google Scholar
• Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther. 2006;5:3162. doi:10.1158/1535-7163.MCT-06-048017172420
   PubMed Web of Science ®Google Scholar
• Su Z, Xing L, Chen Y, et al. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharm. 2014;11(6):1823–1834. doi:10.1021/mp500238m24779677
   PubMedGoogle Scholar
• Huang FYJ, Chen WJ, Lee WY, Lo ST, Lee TW, Lo JM. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int J Mol Sci. 2013;14(2):2862–2874. doi:10.3390/ijms1402286223434652
   PubMed Web of Science ®Google Scholar
• Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep. 2017;7(1):1–13. doi:10.1038/s41598-017-06888-428127051
   PubMedGoogle Scholar
• Kumari S, Bhattacharya D, Rangaraj N, Chakarvarty S, Kondapi AK, Rao NM. Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma. Nanomedicine. 2018;13(20):2579–2596. doi:10.2217/nnm-2018-011030334671
   PubMed Web of Science ®Google Scholar
• Pang Z, Feng L, Hua R, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm. 2010;7(6):1995–2005. doi:10.1021/mp100277h20957995
   PubMedGoogle Scholar
• Zhang J, Xiao X, Zhu J, et al. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomedicine. 2018;13:3039–3051. doi:10.2147/IJN.S16116329861635
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017;24(1):1045–1055. doi:10.1080/10717544.2017.134433428687044
   PubMed Web of Science ®Google Scholar
• Soni V, Kohli D, Jain S. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-fluorouracil. J Drug Target. 2005;13:245–250. doi:10.1080/1061186050010740116051536
   PubMed Web of Science ®Google Scholar
• Lam FC, Morton SW, Wyckoff J, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9(1):1991. doi:10.1038/s41467-018-04315-429777137
   PubMedGoogle Scholar
• Wang X, Zhao Y, Dong S, et al. Cell-penetrating peptide and transferrin co-modified liposomes for targeted therapy of glioma. Molecules. 2019;24:3540. doi:10.3390/molecules24193540
   PubMed Web of Science ®Google Scholar